1. Adhesion molecules: a new target for immunoliposome-mediated drug delivery
- Author
-
M.C. van den Tweel, Gert Storm, Paul A.J. Henricks, L. van Bloois, Daan J.A. Crommelin, A.C. Bloem, Frans P. Nijkamp, and P.G.M. Bloemen
- Subjects
PL ,Umbilical Veins ,BSA ,Biochemistry ,Umbilical vein ,Epithelium ,chemistry.chemical_compound ,Drug Delivery Systems ,HUVEC ,Structural Biology ,HBS ,Immunoliposome ,PBS ,IFN-γ ,VCAM-1 ,ICAM-1 ,Cell adhesion molecule ,Chemistry ,EDTA ,Antibodies, Monoclonal ,FCS ,Intercellular Adhesion Molecule-1 ,Cell biology ,Drug delivery ,SATA ,Monoclonal antibody ,MFI ,medicine.drug_class ,Biophysics ,Bronchi ,MPB-PE ,Cell Line ,DMF ,Genetics ,medicine ,Humans ,Endothelium ,Molecular Biology ,mAb ,PHEPC ,Cell Biology ,Molecular biology ,GamFITC ,TNF-α ,Liposomes ,EPG ,Endothelium, Vascular ,CHOL - Abstract
The anti-ICAM-1 monoclonal antibody F10.2 was conjugated to liposomes to target to cells expressing the cell adhesion molecule ICAM-1. We demonstrate that F10.2 immunoliposomes bind to human bronchial epithelial cells (BEAS-2B) and human umbilical vein endothelial cells (HUVEC) in a specific, dose- and time-dependent manner. It appears that the degree of ICAM-1 expression is the limiting factor in the degree of immunoliposome binding to the cells. These results are a first step in the strategy for specific drug delivery to target sites characterised by increased expression of adhesion molecules.
- Full Text
- View/download PDF